In earnings' conference call, Jhunjhunwala who currently holds 1.12 percent stake in the company threw a volley of questions to the management. The big bull raised questions on Aurobindo Pharma's finance cost, capex, rationale behind investment in vaccines, product launch, potential revenue growth and its fund raising plans.
first published: Aug 24, 2016 02:33 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty holds gain for 4th day, above 25,100 on weekly expiry day | Closing bell
Zoho CEO Mani Vembu On Why India Needs Arattai, Growth Surge And Integrating Businesses | Exclusive
LG Electronics’ Rs 11,607 Cr IPO Opens; Management Charts Out the Road Ahead | IPO Watch Live
Live: Can bulls extend Nifty's rally to the fourth straight day? | Opening Bell
